Shingles shot may shield brain: 33,000 seniors test dementia link

NCT ID NCT07502560

Recruiting now Prevention Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether the Shingrix vaccine, already used to prevent shingles, can also lower the risk of dementia in adults aged 76 and older. Over 33,000 participants in Finland will receive either the vaccine or a placebo. Researchers will track new dementia diagnoses over time to see if the vaccine offers added brain protection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Shingrix (recombinant zoster vaccine)
What this could lead to: If successful, this could show that the shingles vaccine also helps prevent or delay dementia in older adults.
What could go wrong: This is a large trial, but it's testing a secondary effect—the vaccine may not reduce dementia risk. Results are not guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HERPES ZOSTER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease herpes zoster dementia prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HERPES ZOSTER

Contacts and locations

Locations

GSK Investigational Site
RECRUITING

Espoo, 02230, Finland
GSK Investigational Site
RECRUITING

Helsinki, 00100, Finland
GSK Investigational Site
RECRUITING

Jarvenpaa, 04400, Finland
GSK Investigational Site
RECRUITING

Kokkola, 67100, Finland
GSK Investigational Site
RECRUITING

Oulu, 90220, Finland
GSK Investigational Site
RECRUITING

Seinäjoki, 60100, Finland
GSK Investigational Site
RECRUITING

Tampere, 33100, Finland
GSK Investigational Site
RECRUITING

Turku, 20520, Finland

More trials for these conditions

Other studies related to the condition(s) this trial covers.